[Significance of nitrates in contemporary pharmacotherapy of cardiovascular diseases]. 2006

I V Zhirov, and S N Tereshchenko

Results of the use of nitrates in various forms of cardiovascular pathology are presented and problems related to correctness of application of preparations of this group, development of tolerance to them are considered. Results of their use in extracardiac pathology are also outlined.

UI MeSH Term Description Entries
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

I V Zhirov, and S N Tereshchenko
January 1990, Kardiologia polska,
I V Zhirov, and S N Tereshchenko
January 1999, Klinicheskaia meditsina,
I V Zhirov, and S N Tereshchenko
January 1970, Vestnik Akademii meditsinskikh nauk SSSR,
I V Zhirov, and S N Tereshchenko
January 2006, Kardiologiia,
I V Zhirov, and S N Tereshchenko
October 2004, Vnitrni lekarstvi,
I V Zhirov, and S N Tereshchenko
December 2004, Thrombosis and haemostasis,
I V Zhirov, and S N Tereshchenko
January 2010, Kardiologiia,
I V Zhirov, and S N Tereshchenko
March 2002, The American journal of managed care,
I V Zhirov, and S N Tereshchenko
January 2011, Casopis lekaru ceskych,
I V Zhirov, and S N Tereshchenko
January 2015, Cardiovascular & hematological agents in medicinal chemistry,
Copied contents to your clipboard!